Yiming Deng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yiming Deng has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Xuan Sun
Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
2 shared publications Yue Yin
Department of Neurology, Interventional Neuroradiology, Beijing Tiantan Hospital, Capital Medical University, China (M.L., Y.Y., H.C., Y.D.).
2 shared publicationsAnxin Wang
China National Clinical Research Center for Neurological Diseases, Beijing, China
1 shared publicationBaixue Jia
Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
1 shared publicationChangming Wang
Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China
1 shared publicationDapeng Mo
Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
1 shared publication
Latest Publications
- 12 November 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
Sex‐Stratified Outcomes in Balloon Angioplasty for Symptomatic Intracranial Artery Stenosis: The BASIS Subgroup Analysis
Background: The BASIS (Balloon Angioplasty for Symptomatic Intracranial Artery Stenosis) trial demonstrated that balloon angioplasty plus aggressive medical management was superior to aggressive medical management alone for symptomatic intracranial atherosclerotic stenosis. However, whether sex modifies this treatment effect is unknown. Methods: This prespecified secondary analysis of the BASIS randomized controlled trial included 501 patients with symptomatic intracranial atherosclerotic stenosis from 31 Chinese centers (November 2018 to April 2022). Baseline characteristics and outcomes were compared between sexes and across treatment arms within each sex. The primary outcome was stroke or death within 30 days, or ischemic stroke in the qualifying artery territory or revascularization beyond 30 days through 12 months. Results: Among 501 patients (mean age, 58 years), 158 (31.5%) were women. No significant sex‐by‐treatment interaction was observed for primary or key secondary outcomes (all P for interaction >0.05). In sex‐stratified analyses, balloon angioplasty reduced primary outcome risk versus aggressive medical management in men (2.9% versus 11.1%; hazard ratio [HR]=0.21 [95% CI, 0.07–0.65]; P =0.01). In women, the effect favored balloon angioplasty but was not statistically significant (7.8% versus 18.5%; HR=0.37 [95% CI, 0.14–1.01]; P =0.051). Conclusions: No significant interaction between sex and treatment effect was found, suggesting balloon angioplasty's benefit relative to aggressive medical management does not clearly differ by sex. Sex‐stratified results showed significant benefit in men and a nonsignificant trend in women, but the study lacked power for definitive interaction testing, so findings are exploratory. Further research is needed to confirm these findings in broader populations. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT03703635.
- 12 November 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
Sex‐Stratified Outcomes in Balloon Angioplasty for Symptomatic Intracranial Artery Stenosis: The BASIS Subgroup Analysis
Background: The BASIS (Balloon Angioplasty for Symptomatic Intracranial Artery Stenosis) trial demonstrated that balloon angioplasty plus aggressive medical management was superior to aggressive medical management alone for symptomatic intracranial atherosclerotic stenosis. However, whether sex modifies this treatment effect is unknown. Methods: This prespecified secondary analysis of the BASIS randomized controlled trial included 501 patients with symptomatic intracranial atherosclerotic stenosis from 31 Chinese centers (November 2018 to April 2022). Baseline characteristics and outcomes were compared between sexes and across treatment arms within each sex. The primary outcome was stroke or death within 30 days, or ischemic stroke in the qualifying artery territory or revascularization beyond 30 days through 12 months. Results: Among 501 patients (mean age, 58 years), 158 (31.5%) were women. No significant sex‐by‐treatment interaction was observed for primary or key secondary outcomes (all P for interaction >0.05). In sex‐stratified analyses, balloon angioplasty reduced primary outcome risk versus aggressive medical management in men (2.9% versus 11.1%; hazard ratio [HR]=0.21 [95% CI, 0.07–0.65]; P =0.01). In women, the effect favored balloon angioplasty but was not statistically significant (7.8% versus 18.5%; HR=0.37 [95% CI, 0.14–1.01]; P =0.051). Conclusions: No significant interaction between sex and treatment effect was found, suggesting balloon angioplasty's benefit relative to aggressive medical management does not clearly differ by sex. Sex‐stratified results showed significant benefit in men and a nonsignificant trend in women, but the study lacked power for definitive interaction testing, so findings are exploratory. Further research is needed to confirm these findings in broader populations. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT03703635.
- 1 June 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (6) , e153-e154
Coil Embolization of an Infraoptic Anterior Cerebral Artery Aneurysm
- 1 June 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (6) , e153-e154
Coil Embolization of an Infraoptic Anterior Cerebral Artery Aneurysm
- Open Access
- 27 May 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1574948
Time dependency of thrombectomy for large artery atherosclerosis versus cardioembolic stroke subtypes: evidence from the ANGEL-ACT registry
Introduction: In this study, we investigated the differences in clinical outcomes following endovascular thrombectomy among ischemic stroke subtypes caused by large artery atherosclerosis (LAA) versus cardioembolism (CE) and the time-dependent nature of these clinical outcomes based on the stroke subtypes. Methods: Study participants were selected from the Endovascular Treatment Key Technique and Emergency Workflow Improvement of Acute Ischemic Stroke Registry to conduct a post-hoc analysis of a prospective, observational study. We included 1,046 patients, who had either LAA or CE stroke subtypes based on the Trial of Org 10172 in Acute Stroke Treatment criteria, drawn from the thrombectomy cohort. The association between clinical outcomes and time from stroke onset-to-recanalization time (ORT) was analyzed using a logistic regression model.Results: Overall, 545 (52.6%) and 491 (47.4%) patients were included in the LAA and CE groups, respectively. No significant difference was found in the 90-day clinical functional outcome between the LAA and CE patients when ORT was achieved within 240 min. Beyond 240 min, the rate of achieving a modified Rankin Scale score of 0–2 in patients with LAA was higher than that of patients with CE [48.17% versus 38.66%; odds ratio (OR) = 0.678, 95% confidence interval (CI) = 0.521–0.884, p = 0.0040], and after adjustment, the OR was 0.732 (95% CI: 0.537–0.998, p = 0.0486).Conclusion: In cases where the ORT exceeded 240 min, the clinical outcomes of patients with LAA were better than those of patients with CE, demonstrating a stronger time-dependency for achieving a favorable prognosis in patients with cardioembolic stroke.
- 27 May 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1574948
Open AccessTime dependency of thrombectomy for large artery atherosclerosis versus cardioembolic stroke subtypes: evidence from the ANGEL-ACT registry
Introduction: In this study, we investigated the differences in clinical outcomes following endovascular thrombectomy among ischemic stroke subtypes caused by large artery atherosclerosis (LAA) versus cardioembolism (CE) and the time-dependent nature of these clinical outcomes based on the stroke subtypes. Methods: Study participants were selected from the Endovascular Treatment Key Technique and Emergency Workflow Improvement of Acute Ischemic Stroke Registry to conduct a post-hoc analysis of a prospective, observational study. We included 1,046 patients, who had either LAA or CE stroke subtypes based on the Trial of Org 10172 in Acute Stroke Treatment criteria, drawn from the thrombectomy cohort. The association between clinical outcomes and time from stroke onset-to-recanalization time (ORT) was analyzed using a logistic regression model.Results: Overall, 545 (52.6%) and 491 (47.4%) patients were included in the LAA and CE groups, respectively. No significant difference was found in the 90-day clinical functional outcome between the LAA and CE patients when ORT was achieved within 240 min. Beyond 240 min, the rate of achieving a modified Rankin Scale score of 0–2 in patients with LAA was higher than that of patients with CE [48.17% versus 38.66%; odds ratio (OR) = 0.678, 95% confidence interval (CI) = 0.521–0.884, p = 0.0040], and after adjustment, the OR was 0.732 (95% CI: 0.537–0.998, p = 0.0486).Conclusion: In cases where the ORT exceeded 240 min, the clinical outcomes of patients with LAA were better than those of patients with CE, demonstrating a stronger time-dependency for achieving a favorable prognosis in patients with cardioembolic stroke.
- 1 May 2023
- Published by Wolters Kluwer Health in Stroke
- Vol. 54 (5) , 1377-1389
TRIM29 (Tripartite Motif Containing 29) Alleviates NLRC4 (NLR Family CARD Domain Containing Protein 4) Inflammasome Related Cerebral Injury via Promoting Proteasomal Degradation of NLRC4 in Ischemic Stroke
Background: Neuroinflammation plays extremely crucial roles in the neurological damage mediated by ischemic stroke. TRIM29 (tripartite motif containing 29) has previously been proposed to contribute to the regulation of innate immunity, however, the effect of TRIM29 on ischemic stroke induced neurodegenerative processes and neuroinflammation still largely unexplored. In the current article, we aimed to investigate the function and the precise mechanisms of TRIM29 in ischemic stroke. Methods: Middle cerebral artery occlusion mice model and oxygen-glucose deprivation cell model were established as in vivo and in vitro models of ischemic stroke. Quantitative real-time polymerase chain reaction (PCR), Western blot, and ELSIA were used to detect the expression levels of TRIM29, cytokines, and marker proteins. Immunofluorescence assay was performed to examine the extent of cell death. Different truncations were generated, and coimmunoprecipitation assays were used to confirm the protein interaction. Ubiquitination assay was performed to detect the ubiquitination levels. Results: We found that the cerebral ischemia-reperfusion induced injury was aggravated in TRIM29 knockout mice after middle cerebral artery occlusion operation as well as the increased neurological deficits score. TRIM29 expression was also found to be up-regulated upon middle cerebral artery occlusion or OGD administration, and loss of TRIM29 promoted the apoptosis and pyroptosis of neurons and microglial cells induced by middle cerebral artery occlusion or OGD, consistent with the enhanced proinflammatory mediators production and activation of NLRC4 (NLR [NOD-like receptor] family CARD [caspase recruitment domain] domain containing protein 4) inflammasome. Furthermore, we observed that TRIM29 interacted with NLRC4 directly and promoted the K48-linked polyubiquitination of NLRC4, lead to the proteasomal degradation of NLRC4. Conclusions: In conclusion, for the first time, we revealed the role of TRIM29 in ischemic stroke and illustrated the direct relationship between TRIM29 and NLRC4.
- 1 May 2023
- Published by Wolters Kluwer Health in Stroke
- Vol. 54 (5) , 1377-1389
TRIM29 (Tripartite Motif Containing 29) Alleviates NLRC4 (NLR Family CARD Domain Containing Protein 4) Inflammasome Related Cerebral Injury via Promoting Proteasomal Degradation of NLRC4 in Ischemic Stroke
Background: Neuroinflammation plays extremely crucial roles in the neurological damage mediated by ischemic stroke. TRIM29 (tripartite motif containing 29) has previously been proposed to contribute to the regulation of innate immunity, however, the effect of TRIM29 on ischemic stroke induced neurodegenerative processes and neuroinflammation still largely unexplored. In the current article, we aimed to investigate the function and the precise mechanisms of TRIM29 in ischemic stroke. Methods: Middle cerebral artery occlusion mice model and oxygen-glucose deprivation cell model were established as in vivo and in vitro models of ischemic stroke. Quantitative real-time polymerase chain reaction (PCR), Western blot, and ELSIA were used to detect the expression levels of TRIM29, cytokines, and marker proteins. Immunofluorescence assay was performed to examine the extent of cell death. Different truncations were generated, and coimmunoprecipitation assays were used to confirm the protein interaction. Ubiquitination assay was performed to detect the ubiquitination levels. Results: We found that the cerebral ischemia-reperfusion induced injury was aggravated in TRIM29 knockout mice after middle cerebral artery occlusion operation as well as the increased neurological deficits score. TRIM29 expression was also found to be up-regulated upon middle cerebral artery occlusion or OGD administration, and loss of TRIM29 promoted the apoptosis and pyroptosis of neurons and microglial cells induced by middle cerebral artery occlusion or OGD, consistent with the enhanced proinflammatory mediators production and activation of NLRC4 (NLR [NOD-like receptor] family CARD [caspase recruitment domain] domain containing protein 4) inflammasome. Furthermore, we observed that TRIM29 interacted with NLRC4 directly and promoted the K48-linked polyubiquitination of NLRC4, lead to the proteasomal degradation of NLRC4. Conclusions: In conclusion, for the first time, we revealed the role of TRIM29 in ischemic stroke and illustrated the direct relationship between TRIM29 and NLRC4.
- Open Access
- 1 September 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (63) , 107312-107322
Increased local connectivity of brain functional networks during facial processing in schizophrenia: evidence from EEG data
Increased local connectivity of brain functional networks during facial processing in schizophrenia: evidence from EEG data Increased local connectivity of brain functional networks during facial processing in schizophrenia: evidence from EEG data
- 1 September 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (63) , 107312-107322
Open AccessIncreased local connectivity of brain functional networks during facial processing in schizophrenia: evidence from EEG data
Increased local connectivity of brain functional networks during facial processing in schizophrenia: evidence from EEG data Increased local connectivity of brain functional networks during facial processing in schizophrenia: evidence from EEG data